TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH - News), today announced that it has licensed United States Patent 7,336,995 "Method and Apparatus for Tachycardia Detection and Treatment" from the Massachusetts Institute of Technology (MIT) under the terms of its umbrella technology license agreement with MIT. This broad patent covers the use of implantable devices such as pacemakers and defibrillators to measure T-Wave Alternans from intra-cardiac signals, and to subsequently initiate therapy in order to prevent the development of arrhythmias which may lead to sudden cardiac death. Implantable defibrillators currently treat such arrhythmias only after they have been initiated, typically with a high-energy shock. A strategy to predict such rhythms before they occur could allow for preventive strategies, potentially avoiding imminent symptomatic episodes with the delivery of painless therapies.
